RIABNI® HAS THE SAME DOSING SCHEDULE AS RITUXAN®1
CD20-POSITIVE B-Cell NON-HODGKIN'S LYMPHOMA (NHL)
Schedule |
RIABNI® dose |
|---|---|
|
Day 1 of each cycle of chemotherapy (≤ 8 doses) In patients with a complete or partial response, as single-agent maintenance therapy every 8 weeks for 12 doses, beginning 8 weeks after the last dose of chemotherapy Day 1 of each cycle of chemotherapy (≤ 8 doses) In patients with a complete or partial response, as single-agent maintenance therapy every 8 weeks for 12 doses, beginning 8 weeks after the last dose of chemotherapy |
RIABNI® dose 375 mg/m2 |
Schedule |
RIABNI® dose |
|---|---|
| Once weekly for 4 or 8 doses | RIABNI® dose 375 mg/m2 |
Schedule |
RIABNI® dose |
|---|---|
| Once weekly for 4 doses | RIABNI® dose 375 mg/m2 |
Schedule |
RIABNI® dose |
|---|---|
|
Following 6-8 cycles of CVP chemotherapy: Once weekly for 4 doses at 6-month intervals (16 doses maximum) |
RIABNI® dose 375 mg/m2 |
Schedule |
RIABNI® dose |
|---|---|
| Day 1 of each cycle of chemotherapy (≤ 8 infusions) | RIABNI® dose 375 mg/m2 |
Chronic lymphocytic leukemia (CLL)
Schedule |
RIABNI® dose |
|
|---|---|---|
| Cycle 1: One day prior to initiation of FC chemotherapy | RIABNI® dose 375 mg/m2 | |
| Cycles 2-6: Day 1 of FC chemotherapy cycles (every 28 days) | RIABNI® dose Cycle 1: 375 mg/m2 | |
| Cycles 2-6: 500 mg/m2 | Cycles 2-6: Day 1 of FC chemotherapy cycles (every 28 days) | 500 mg/m2 |
- CVP = cyclophosphamide, vincristine, prednisone; FC = fludarabine, cyclophosphamide.
Find and download additional dosing resources
RIABNI® has the same administration and infusion rates as Rituxan®1
ADMINISTRATION GUIDELINES
- Interrupt the infusion or slow the infusion rate for infusion-related reactions
- See Boxed WARNINGS, Dosage and Administration, Warnings and Precautions, and Adverse Reactions sections of the full Prescribing Information
- Initiate infusion at a rate of 50 mg/hr
- In the absence of infusion toxicity, increase rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr
- Initiate infusion at a rate of 100 mg/hr
- In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr
If patients did not experience a Grade 3 or 4 infusion-related adverse event during Cycle 1, a 90-minute infusion can be administered in Cycle 2 with a glucocorticoid-containing chemotherapy regimen. If the 90-minute infusion is tolerated in Cycle 2, the same rate can be used when administering the remainder of the treatment regimen (through Cycle 6 or 8).
- Initiate at a rate of 20% of the total dose given in the first 30 minutes and the remaining 80% of the total dose over the next 60 minutes
- Patients who have clinically significant cardiovascular disease or who have a circulating lymphocyte count ≥ 5000/mm3 before Cycle 2 should not be administered the 90-minute infusion